AI Giants, Nuclear Bets, Tariffs Steer a Santa Rally As S&P 500, Gold, Silver Hit Records – December 23, 2025 -( $AAPL $AVGO $EPRX $GOVX $INTG $MDLN $NVDA $PLTR $RIO $TSM Rise!)

Wall Street tiptoed into the holiday break on Tuesday with the air of a market that has already opened its presents and is now just admiring the wrapping paper. Stocks drifted rather than surged, but under the surface, big tech, nuclear hopefuls and a fresh crop of SPACs kept traders awake enough to postpone that second eggnog.

Indexes: Surfing Into Christmas

The major U.S. indexes spent the day in classic pre-holiday mode with modest moves on light volume, but still cushioned by a stronger growth backdrop. The S&P 500 closed up .46% at 6.906.79, The Dow 30 called up .16% at 48,442.41 & the Nasdaq closed up .57% at 23,561.84, while the small caps cooled off falling .65% at 2,542.20.

The latest economic calendar shows U.S. durable goods orders rebounded 0.5% in December after a 1.5% drop, hinting at firmer capex appetite heading into 2026 even as consensus had braced for another decline. At the same time, an updated GDP release calendar confirms that third‑quarter real GDP grew at a robust 4.3% annual rate, with the Bureau of Economic Analysis rescheduling key releases to land today because of the earlier shutdown, underscoring a growth backdrop strong enough to support equities even as policy normalizes.

Macro: GDP, Confidence, Tariffs and the Shutdown

Washington, despite itself, continues to serve as the market’s favorite unpriced risk factor. The BEA’s latest guidance confirms that the initial estimate for third‑quarter 2025 GDP, released today as part of a revised post‑shutdown schedule, showed 4.3% annualized growth, powered by consumer spending, exports and government outlays even as investment softened. Consumer psychology is less exuberant: December confidence has slipped to its lowest level since President Donald Trump’s new tariff regime took effect in April, reflecting unease about prices and trade even as the headline data still look expansionary. The tariff machine itself remains very much alive; live coverage of the administration’s trade policy shows the White House preparing an additional wave of levies on Chinese semiconductors by mid‑2027, with officials even floating the prospect of $2,000 rebate checks as political lubrication.

The government shutdown that disrupted the data calendar earlier this quarter continues to cast a procedural shadow rather than an existential one. Trade‑facing agencies such as the U.S. Trade Representative have been designated essential, allowing tariff policy and negotiations to proceed even as other functions have been curtailed, limiting immediate market fallout but adding to operational friction for businesses dependent on federal approvals. The Fed, for its part, has already delivered its holiday gift: at its December meeting, the FOMC cut the federal funds rate by 25 basis points to a 3.50%–3.75% target range—the third cut since September—while signaling a more patient stance heading into 2026. The latest dot plot and commentary suggest policymakers now envision the policy rate settling in the low‑3% area by 2027, a path that supports risk assets but leaves enough yield to keep cash from feeling entirely passé. Treasury yields along the curve have firmed a touch since early December—with the two‑ and ten‑year notes both up only single‑digit basis points—leaving the curve still relatively flat but far less ominously inverted than during the 2022–2023 tightening cycle.

Commodities and Crypto: Quiet Shine, Measured Drip

Outside of equities, the year‑end picture is one of controlled enthusiasm. Gold remains the overachiever of 2025 closing at $4.517.30/oz.: global market summaries highlight that bullion recently notched fresh record highs, with spot prices grinding higher again this week as investors hedge policy and geopolitical risk even against a backdrop of strong growth. Silver also jumped a out +3.92% today to close above $70 at $71.275/oz. Oil closed $58.46, +.78% today and has been behaving more like a disciplined guest than a life‑of‑the‑party spoiler—recent quotes show West Texas Intermediate easing fractionally in global trading, reflecting ample supply, steady demand and a market that has apparently decided to postpone its next crisis until after the holidays. Bitcoin traded near the $88k level again today and other major cryptocurrencies, meanwhile, continue to trade with a gentle upward bias, with recent data showing incremental gains alongside modest moves in ether, giving digital‑asset bulls just enough validation to keep their year‑end decks bullish.

IPOs, SPACs and Deal Flow

Even this late in December, the new‑issue calendar refuses to fully shut down for the holidays. On the IPO front, the SPAC complex is doing the heavy lifting: Silicon Valley Acquisition Corp. has priced a $200 million initial public offering at $10 per unit, with 20 million units listing on Nasdaq under the ticker SVAQU starting today and each unit bundling one Class A share and half of a warrant exercisable at $11.50. Industry trackers note that this deal joins a wave of late‑year blank‑check listings, with specialized sites flagging multiple SPAC pricings this month and pushing 2025’s SPAC count well past last year’s tally. Across the broader U.S. market, IPO statisticians report that 2025 has already produced roughly 347 offerngs, more than 55% above 2024’s pace by this point in the year, fueled by large‑cap deals such as Medline’s (MDLN, $43.70, +3.60%) multibillion‑dollar float and continued appetite for growth and AI‑adjacent stories.

Traditional M&A is finishing the year with a flourish, even if today’s tape lacks a single market‑defining blockbuster. In media and software, Warner Bros. Discovery’s strategic maneuvers have helped frame a 2025 deal environment that has already seen ServiceNow agree to buy cybersecurity firm Armis for about $7.75 billion, expanding its security footprint just as AI‑driven observability becomes critical to large enterprises. Tech and infrastructure consolidation remains a major theme: IBM has closed or announced multiple large transactions over the year—among them the completed $6.4 billion acquisition of HashiCorp and an $11 billion agreement for streaming‑data specialist Confluent—while industry surveys continue to highlight that U.S. and global deal counts remain below 2021’s euphoria but structurally healthy for late‑cycle conditions. In advertising and media, specialists tally more than 400 deals this year across martech, adtech and digital content platforms, with 2025 on track to surpass 2024’s total and confirm that scale, data and targeted AI remain the dominant acquisition currencies heading into 2026.

Single‑Name Highlights: Pharmaceuticals, Chips & AI

A cluster of marquee names drove much of today’s narrative as markets continued to sort long‑duration growth from tactical trades. In pharmaceuticals, Eli Lilly (LLY) remains at the center of the obesity‑drug and diabetes trade, with recent coverage emphasizing how the company’s weight‑loss franchise has reshaped expectations for long‑term revenue and margins even as investors now parse each update for hints about capacity, pricing and competition. In semiconductors, Taiwan Semiconductor Manufacturing Company (TSM, $297.44, +1.42%), Nvidia (NVDA, $189.21, +3.01%), Micron Technology and Intel all sit at the intersection of strong AI demand and evolving trade policy; the administration’s latest tariff roadmap explicitly targets Chinese chips with new levies slated for mid‑2027, a long‑dated overhang that could reshape global foundry and memory investment even if near‑term demand for AI accelerators remains robust. Nvidia in particular continues to benefit from the AI infrastructure boom highlighted in recent global‑equity reports, which note that megacap AI names such as Tesla and Nvidia have led the latest leg of the global rally, helping the S&P 500 erase earlier December losses and putting it on course for an unusually long monthly winning streak.

Apple (AAPL, $272.36, +.56%), Meta (META, $664.94, +.52%) and other platform giants remain in the slipstream of this trade, with investors treating them as the “cash‑flow ballast” for portfolios tilted toward AI‑hardware winners and high‑beta software names. Broadcom’s (AVGO, $349.32, +2.30%) strategic positioning in custom silicon and connectivity continues to anchor it firmly to the AI data‑center build‑out, as large‑cap tech M&A throughout 2025 has reinforced the value of integrated hardware‑software stacks in the cloud and networking layers. Nokia (NOK, $6.53), sitting farther from the AI spotlight, remains more directly exposed to global 5G and network‑spending cycles; infrastructure consolidation such as HPE’s completed $13.4 billion acquisition of Juniper Networks this summer underscores the intense competition in the carrier and enterprise‑network stack in which Nokia must continue to defend share.

Nuclear, Real Estate Tech and Defense‑Grade Data

Among the more speculative darlings, Oklo (OKLO, $81.88) continues to trade like a proxy on the entire advanced‑nuclear thesis rather than a conventional utility. Recent analyses show that after peaking near $175 in October, the stock has fallen more than 50% but still sports year‑to‑date gains north of 250%, with a market cap in the low‑teens billions and a share price in the low‑$80s today on an intraday range roughly between $80.80 and $84.95. Commentators have flagged that valuation as a high‑risk bet on a 14‑gigawatt customer pipeline and regulatory progress, but also as a reminder that Oklo remains pre‑revenue, with operating losses, share issuance and execution risk all squarely on the table for 2026 and beyond.

In housing and real‑estate technology, Opendoor (OPEN, $6.27) has spent most of 2025 as a “volatility with a ticker” story, as the company’s AI‑driven pricing and acquisition strategy runs headlong into a still‑fragile housing market. Recent coverage this month noted a single‑day slide of more than 7%, tied in part to insider selling and persistent operating losses, even as separate analysis points out that the shares have nonetheless surged more than 300% this year on hopes that a “default to AI” strategy can finally deliver breakeven by 2026.

Palantir Technologies (PLTR, $194.13, +.08%) sits in a more mature corner of the AI story, with 2025 marked by continued contract wins and expansion of its government and commercial analytics platforms to ride the same data‑intensive wave reshaping cyber, cloud and observability markets. Oracle likewise continues to pitch itself as a cloud‑and‑data hybrid rather than a legacy software vendor, benefiting indirectly from the same AI data‑center build‑out that has lifted Nvidia and Broadcom, even as it faces intense competition from hyperscalers and the next generation of AI‑native platforms. McDonald’s, Rio Tinto (RIO, $80.97, +1.09%) and other more cyclical or commodity‑exposed names, meanwhile, remain tied to the macro narrative: a 4.3% GDP growth rate, record gold and firm but orderly oil prices are generally good news for miners and consumer bellwethers, though the resilience of tariffs and the potential for renewed trade friction in 2026 ensure that even the most global of brands will not be spared the occasional macro headline risk.

Vista Partners Watchlist Updates

Modular Medical, Inc. (Nasdaq: MODD., $.3337), a leader in innovative insulin delivery technology targeting the $3 billion adult “almost-pumpers” diabetes market with user-friendly, affordable patch pumps, announced (Dec. 10) that it had priced an underwritten public offering (the “offering”) of 12,173,000 shares of its common stock and accompanying warrants to purchase 6,086,500 shares of its common stock. Each two shares of common stock are being offered and sold together with one accompanying warrant at a combined offering at a price of $0.77, yielding an effective price of $0.38 per share and $0.01 per warrant. The warrants will have an exercise price of $0.45 per share, are exercisable immediately upon issuance and will expire five years following the date of issuance. In connection with the offering, Modular Medical has granted the underwriter a 30-day option to purchase up to an additional 15% of common shares and/or warrants at the public offering price, less underwriting discounts and commissions. The over-allotment option may be elected with respect to, at the underwriter’s sole discretion, shares and warrants together, solely shares, solely warrants, or any combination thereof. Newbridge Securities Corporation is acting as the sole bookrunner for the offering. Assuming no exercise of the over-allotment option, the gross proceeds to the Company from the offering are expected to be approximately $4.68 million, before deducting underwriting discounts, commissions, and estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering to fund operations and for working capital and general corporate purposes, including capital expenditures.

On Nov. 17, Modular announced Institutional Review Board (“IRB”) approval to conduct an in-house study of its next-generation Pivot™ insulin delivery system using insulin on people with diabetes (the “Study”). Pursuant to U.S. Food and Drug Administration (“FDA”) regulations, an IRB is a group that has been formally designated to review and monitor biomedical research involving human subjects. The Study will simulate real-world conditions by delivering insulin to adult participants to gather critical data on device function and usability and obtain user feedback. Modular Medical’s Pivot tubeless patch pump aims to enhance accessibility for underserved patients with diabetes and drive market penetration and expansion.

On Nov. 14, Modular Medical announced the 510(k) premarket submission of its next generation Pivot™ tubeless patch pump to the U.S. Food and Drug Administration (the “FDA”). The Company expects to commence the commercial launch of its Pivot pump in Q1 2026. On Nov. 3, Modular Medical the successful validation of its Pivot controller line, a critical milestone in preparing for the commercial launch of its Pivot patch pump targeted for Q1 2026. The Pivot controller line validation further demonstrates manufacturing readiness for high-volume production, positioning Modular Medical to meet the growing demand in the diabetes treatment market for advanced technology.

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX, $7.19, +2.71%), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize local, controlled drug delivery for diseases with significant unmet need, announced (Nov. 13) the second set of 52-week follow up data from its ongoing Phase 1b/2a RESOLVE trial evaluating a single administration EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). James A. Helliwell, Chief Executive Officer of Eupraxia stated,“These data further highlight the strong durability and tolerability profile of EP-104GI, reinforcing its potential to become a convenient, once-a-year treatment that fits seamlessly into routine disease management by aligning with annual patient endoscopies. The Cohorts 5 & 6 patients – the only groups to have reached 52 weeks in the trial – are demonstrating levels of symptom relief that is durable and clinically meaningful – we are very encouraged by this outcome. We’re also pleased that our previously announced 52-week data were presented as a late-breaking presentation at the American College of Gastroenterology Annual Scientific Meeting (ACG). These new results build on that momentum. Given that current EoE therapies often struggle with long-term adherence, we believe a durable, once-yearly treatment could meaningfully improve patient outcomes and establish EP-104GI as a preferred option for both physicians and their patients.”

GeoVax Labs, Inc. (Nasdaq: GOVX, $.1907, +10.68%), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, announced (Dec. 19) that it has entered into definitive securities purchase agreements with several institutional and individual investors for the purchase and sale of approximately 13.2 million units, each comprised of one share of the Company’s common stock and warrants, as described below, to purchase shares of the Company’s common stock, at a price of $0.245 per unit in a public offering. The Company will issue warrants to purchase up to approximately 26.5 million shares of common stock. The warrants will have an exercise price of $0.245 per share, will be exercisable immediately following the date of issuance and will have a term of five years following the date of issuance. Roth Capital Partners is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from this offering are expected to be approximately $3.2 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes. The closing of the offering is expected to occur on or about December 22, 2025, subject to the satisfaction of customary closing conditions.

GeoVax announced (Dec. 18) the publication of a peer-reviewed article in Frontiers in Immunology titled: “Multi-antigen MVA-vectored SARS-CoV-2 vaccine, GEO-CM04S1, induces cross-protective immune responses to ancestral and Omicron variants.” The study provides definitive preclinical evidence that GeoVax’s multi-antigen COVID-19 vaccine candidate, GEO-CM04S1, delivers full cross-variant protection, driven predominantly by robust T-cell responses, even in the absence of neutralizing antibodies. The findings reinforce the design philosophy behind GeoVax’s MVA-based, multi-antigen platform and provide mechanistic insight that is increasingly relevant for immunocompromised individuals, who often fail to respond optimally to the first-generation COVID-19 vaccines.

GeoVax announced (Dec. 17) the successful completion of fill-finish for the initial clinical batch of GEO-MVA, its next-generation Mpox/smallpox vaccine. The product has now entered final release evaluation, the concluding quality-control and compliance process required before shipment for clinical use, positioning the Company for Phase 3 immunobridging trial start-up activities in Q1 2026. Fill-finish – the sterile, cGMP-regulated process of filling, sealing, and packaging vaccine vials – marks the last manufacturing step before a vaccine may enter clinical study supply channels. With fill-finish complete and GEO-MVA now undergoing final release evaluation, GeoVax has moved into the final pre-clinical-deployment phase of its EMA-aligned clinical program. In June 2025, the European Medicines Agency (EMA) Scientific Advice confirmed that a single Phase 3 immunobridging study demonstrating immune comparability to the approved MVA vaccine, Imvanex(R), would be sufficient to evaluate GEO-MVA’s efficacy. This provides a clear, accelerated regulatory path to licensure. This milestone coincides with increasing Mpox activity globally – including expanding Clade I outbreaks in Africa and emerging cases in the United States – exposing vulnerabilities associated with global dependence on a sole foreign MVA vaccine supplier. GEO-MVA is designed to expand supply, diversify sources, and strengthen biodefense infrastructure.

Volato Group, Inc. (NYSE American: SOAR, $1.0087) and M2i Global, Inc. (MTWO, $.071), a company specializing in the development and execution of a complete global value supply chain for critical minerals, today announced key developments in its pending all-stock merger with M2i Global, Inc.. Volato has filed the Registration Statement on Form S-4 with the U.S. Securities and Exchange Commission (the “SEC”), following the SEC’s completion of its review of the initial confidential submission. With the reopening of federal agencies following the recent government shutdown, both companies now anticipate closing the merger in the first quarter of 2026, pending completion of SEC review and shareholder approval.

On Dec. 23, Volato Group, Inc. announced preliminary financial guidance for the fourth quarter and full year ending December 31, 2025, reflecting continued execution against its strategic and balance sheet objectives. For the fourth quarter of 2025, Volato expects to report revenue between $27 million and $28 million. For the full year 2025, the Company anticipates total revenue between $78 million and $79 million, with net income of $6 million to $8 million. These results reflect a year of meaningful progression aligning operational performance with Volato’s long-term growth initiatives and advancing its pending merger with M2i Global, Inc. (OTC: MTWO). During 2025, Volato also made substantial progress strengthening its balance sheet. As of September 30, 2025, the Company reduced total liabilities to $9.5 million, satisfying the debt reduction condition required under its pending merger agreement with M2i Global, Inc. (OTC: MTWO). Volato expects continued improvement in its capital structure as it advances toward a targeted first-quarter 2026 closing of the transaction. “Our 2025 results reflect a year of transformation and disciplined balance sheet execution,” said Mark Heinen, Chief Financial Officer of Volato. “We made significant progress reducing liabilities while sharpening our focus on scalable, technology-driven businesses that are designed to complement and strengthen the M2i Global platform over the long term.”

On Dec. 18, Volato Group, Inc. and M2i Global, Inc. announced that they applaud the recent December 11, 2025 announcement from the U.S. Department of State whereby Pax Silica, a U.S.-led strategic initiative to build a secure, prosperous, and innovation driven silicon supply chain—from critical minerals and energy inputs to advanced manufacturing, semiconductors, AI infrastructure, and logistics, was formed.

Volato Group, Inc. (NYSE American: SOAR) announced recently that it has set a preliminary date of February 26, 2026 and preliminary record date of January 17, 2026 for a special meeting of shareholders to vote on the proposed merger with M2i Global, Inc. (MTWO) and related matters. The preliminary meeting date and record date remain subject to applicable regulatory and exchange requirements, including the effectiveness of Volato’s Registration Statement on Form S-4 (File No. 333-292132) (the “Registration Statement”) filed with the U.S. Securities and Exchange Commission (“SEC”) and the mailing of definitive proxy materials to shareholders. The proposed merger creates a combined company built for scale. M2i Global brings a platform focused on critical minerals and national supply chain resilience, while Volato contributes proven aviation technology, software capability, and an established track record of operational execution. Together, the companies aim to participate in a U.S. critical minerals market estimated at more than $320 billion annually.

Serina Therapeutics (NYSE American: SER, $2.57), Alabama-based biotech is betting its proprietary POZ platform and reimagined approach to apomorphine delivery may redefine the treatment paradigm for patients who have exhausted standard oral therapies. On Dec. 11, Serina announced the appointment of Joshua Thomas, Ph.D., as Vice President and Head of Chemistry. He will oversee internal and external chemistry efforts to optimize POZ-based candidates, supporting efficient translation from discovery through development.

On Dec. 10,Serina announced that it has submitted a complete response to the U.S. Food and Drug Administration’s (“FDA”) clinical hold letter for SER-252, the Company’s lead program for advanced Parkinson’s disease. As previously disclosed, the FDA placed the Company’s Investigational New Drug (“IND”) application for SER-252 on clinical hold pending additional information related to a commonly used formulation excipient. On November 25, 2025, the FDA issued a formal full clinical hold letter specifying the information required to permit initiation of the planned Phase 1b registrational study, SER-252-1b. The issues identified by the FDA do not relate to the apomorphine active drug substance, its mechanism of action, the use of the enFuse device (Enable Injections) or the broader 505(b)(2) NDA development pathway previously discussed with the Agency.

The InterGroup Corporation (NASDAQ: INTG, $27.55, +9.76%) reported (Nov. 17) results for the three months ended September 30, 2025. John V. Winfield, Chairman and Chief Executive Officer, said: “We continue to observe signs of stabilization and recovery across the San Francisco hospitality market, including improving convention calendars, tourism indicators, and business travel activity. On the investment side, our marketable securities activity remained modest with a small net gain, consistent with our emphasis on liquidity and risk discipline.”

DoubleVerify Holdings Inc. (DV) closed at $11.25.. DoubleVerify, which built its franchise on media verification and ad performance analytics, is now the first badged TikTok Marketing Partner focused specifically on attention measurement, tapping impression-level signals from the platform. Brands gain a granular view of how exposure and user interaction come together across TikTok formats, ad sets, creatives, and objectives, effectively treating every swipe as a tiny A/B test.

Sources

1. https://tradingeconomics.com/united-states/calendar
2. https://www.bea.gov
3. https://www.bea.gov/news/blog/2025-11-24/economic-release-schedule-updates-0
4. https://www.usnews.com/news/business/articles/2025-12-23/consumer-confidence-slides-in-december-to-lowest-level-since-us-tariffs-rolled-out-in-april
5. https://finance.yahoo.com/news/live/trump-tariffs-live-updates-us-to-impose-tariffs-on-chinese-chips-in-mid-2027-hassett-says-2k-rebate-checks-likely-231853525.html
6. https://www.bondsavvy.com/fixed-income-investments-blog/fed-dot-plot
7. https://finance.yahoo.com/news/government-shutdown-raises-questions-status-201236929.html
8. https://www.cnbc.com/2025/12/10/fed-interest-rate-decision-december-2025-.html
9. https://www.nnrglobal.com/insight/u-s-government-shutdown-update-2025/
10. https://tradingeconomics.com/united-states/interest-rate
11. https://www.ndtvprofit.com/markets/global-stock-market-news-december-23-dow-jones-nikkei-hang-seng-s-and-p-500-nasdaq
12. https://stockanalysis.com/ipos/2025/
13. https://www.quiverquant.com/news/Silicon+Valley+Acquisition+Corp.+Announces+Pricing+of+Initial+Public+Offering+of+20+Million+Units
14. https://www.investing.com/news/stock-market-news/silicon-valley-acquisition-corp-prices-200-million-ipo-at-10-per-unit-432SI-4420202
15. https://www.spacinsider.com/news/new-ipos
16. https://www.globenewswire.com/news-release/2025/12/22/3209575/0/en/Silicon-Valley-Acquisition-Corp-Announces-Pricing-of-200-Million-Initial-Public-Offering.html
17. https://www.iposcoop.com
18. https://www.investors.com/news/ipo-stocks-klarna-circle-internet-figma/
19. https://www.crn.com/news/channel-news/2025/the-10-biggest-tech-m-a-deals-of-2025
20. https://www.bloomberg.com/news/newsletters/2025-12-23/warner-bros-discovery-s-masterful-m-a-move
21. https://www.paulweiss.com/insights/client-memos/ma-at-a-glance-december-2025
22. https://www.adweek.com/media/2025-m-a-mergers-acquisitions-deals-media-advertising-list/
23. https://robinhood.com/us/en/stocks/OKLO/
24. https://www.fool.com/investing/2025/12/22/is-oklo-stock-a-buy-now/
25. https://www.ainvest.com/news/oklo-stock-high-risk-speculative-bet-strategic-play-future-nuclear-energy-2512/
26. https://finance.yahoo.com/quote/OKLO/
27. https://stockstotrade.com/news/opendoor-technologies-inc-open-news-2025_12_12/
28. https://www.fool.com/investing/2025/12/19/opendoor-technologies-stock-320-in-2025-buy-2026/
29. https://finance.yahoo.com/quote/OPEN/history/
30. https://www.zacks.com/stock/news/2808104/will-opendoors-default-to-ai-strategy-deliver-real-returns
31. https://www.npr.org/2025/12/23/nx-s1-5651932/economy-delayed-gdp-tariffs
32. https://www.politico.com/news/2025/12/23/trump-economy-consumer-spending-00704326
33. https://thehill.com/homenews/administration/5660934-donald-trump-tariffs-ecnomy-gdp/
34. https://www.ksat.com/news/politics/2025/12/23/a-look-at-the-experts-racing-to-decode-trumps-tariff-rules/
35. https://www.whitehouse.gov/presidential-actions/2025/12/providing-for-the-closure-of-executive-departments-and-agencies-of-the-federal-government-on-december-24-2025-and-december-26-2025/
36. https://finance.yahoo.com/news/government-shutdown-raises-questions-status-212147065.html
37. https://www.benzinga.com/calendars/m-a
38. https://www.stocktitan.net/sec-filings/IAS/8-k-integral-ad-science-holding-corp-reports-material-event-ab6c511cb4cd.html
39. https://www.reddit.com/r/Tariffs/comments/1nzmtdg/5_days_into_the_shutdown_politics_just_became_a/
40. https://www.schwab.com/learn/story/fomc-meeting
41. https://www.nasdaq.com/market-activity/ipos
42. https://finviz.com/news/260747/first-the-generation-essentials-group-sponsored-spac-announces-successful-closing-of-150-million-ipo
43. https://fred.stlouisfed.org/releases/calendar
44. https://www.newyorkfed.org/research/calendars/nationalecon_cal
45. https://www.marketwatch.com/economy-politics/calendar
46. https://www.dow-jones-djia.com/2025/12/23/the-dow-market-happenings-for-tuesday-december-23-2025-ibm-ibm-302-79-up-37-74-ytd/
47. https://www.census.gov/economic-indicators/calendar-listview.html
48. https://www.cnbc.com/2025/11/23/stock-market-today-live-updates.html
49. https://tradingeconomics.com/calendar
50. https://www.moneycontrol.com/news/business/markets/stock-market-live-updates-gift-nifty-indicates-a-firm-opening-us-asian-markets-gain-liveblog-13738255.html
51. https://www.wastedive.com/news/2025-notable-waste-and-recycling-acquisitions/808593/
52. https://us.econoday.com
53. https://blog.liquide.life/liquide-post-market-summary-23rd-december-2025/
54. https://www.atlantafed.org/cqer/research/gdpnow
55. https://nz.finance.yahoo.com/calendar/ipo?day=2025-12-23
56. https://stockinvest.us/stock/OPEN
57. https://www.stocktitan.net/news/SCPQ/social-commerce-partners-corporation-announces-pricing-of-100-000-ol6kz6tb8cby.html
58. https://www.nyse.com/ipo-center/recent-ipo
59. https://www.perplexity.ai/finance/OKLO/history